Mikafungin Teva (Micafungin)

Micafungin is an echinocandin antifungal used to treat invasive Candida infections.

• Invasive candidiasis: effective in clearing bloodstream and deep‑tissue Candida infections.
• Esophageal candidiasis: resolves mucosal lesions and associated symptoms.
• Candida peritonitis and intra‑abdominal abscesses: aids in infection control when combined with surgical management.
• Prophylaxis in hematopoietic stem cell transplantation: reduces incidence of breakthrough Candida infection.

• Micafungin inhibits the enzyme β‑1,3‑D‑glucan synthase, which is essential for synthesis of 1,3‑β‑D‑glucan, a critical component of the fungal cell wall. By disrupting cell‑wall construction, the drug leads to osmotic instability and fungal cell lysis, providing fungicidal activity against most Candida species. It shows low affinity for human enzymes, resulting in a favorable safety profile. The inhibition is concentration‑dependent and persists after plasma levels decline.

Micafungin may be associated with a range of adverse reactions, most of which are mild to moderate in severity.

Common Side Effects

• Elevated liver enzymes: transient increases in ALT or AST.
• Fever: mild to moderate temperature rise.
• Nausea: occasional feeling of stomach upset.
• Infusion‑related reactions: erythema, flushing, or mild hypotension.

Serious or Rare Side Effects

• Severe hepatic dysfunction: marked elevation of transaminases or bilirubin.
• Anaphylaxis: rare but potentially life‑threatening allergic reaction.
• Stevens‑Johnson syndrome/TEN: severe skin reactions that may be life‑threatening.

When using Micafungin, clinicians should observe several safety considerations.

• Renal function: monitor serum creatinine in patients with pre‑existing kidney disease.
• Hepatic function: assess liver enzymes before and during therapy.
• Drug interactions: review concomitant medications that affect hepatic metabolism.
• Pregnancy and lactation: use only if potential benefit justifies risk, as safety data are limited.
• Patient monitoring: observe for signs of hypersensitivity or infusion reactions.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Micafungin can interact with other medicines; awareness of the interaction level helps guide management.

Major Interactions (Avoid)

• Cytochrome P450 inducers (e.g., rifampicin): may reduce micafungin exposure.
• Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase micafungin levels, raising toxicity risk.

Moderate Interactions (Monitor Closely)

• Immunosuppressants (e.g., tacrolimus, cyclosporine): may require dose adjustment.
• Antifungal agents with overlapping spectrum (e.g., fluconazole): consider additive toxicity.
• Concomitant nephrotoxic drugs: monitor renal function closely.